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Age-related sarcopenia and dynapenia are associated with frailty and metabolic diseases. Resistance
exercise training (RET) adjuvant to evidence-based nutritional intervention(s) have been shown as
mitigating strategies. Given that b-hydroxy-b-methyl-butyrate (HMB) supplementation during RET im-
proves lean body mass in younger humans, and that we have shown that HMB acutely stimulates muscle
protein synthesis (MPS) and inhibits breakdown; we hypothesized that chronic supplementation of HMB
free acid (HMB-FA) would enhance MPS and muscle mass/function in response to RET in older people.
We recruited 16 healthy older men (Placebo (PLA): 68.5 ± 1.0 y, HMB-FA: 67.8 ± 1.15 y) for a rando-
mised double-blind-placebo controlled trial (HMB-FA 3  1 g/day vs. PLA) involving a 6-week unilateral
progressive RET regime (6  8 repetitions, 75% 1-RM, 3 $ wk1). Deuterium oxide (D2O) dosing was
performed over the ﬁrst two weeks (0e2 wk) and last two weeks (4e6 wk) with bilateral vastus lateralis
(VL) biopsies at 0e2 and 4e6 wk (each time 75 ± 2 min after a single bout of resistance exercise (RE)) for
quantiﬁcation of early and later MPS responses and post-RE myogenic gene expression. Thigh lean mass
(TLM) was measured by DXA, VL thickness and architecture (ﬁbre length and pennation angle) by
ultrasound at 0/3/6 wk, and strength by knee extensor 1-RM testing and MVC by isokinetic dyna-
mometry (approx. every 10 days).
RET induced strength increases (1-RM) in the exercised leg of both groups (398 ± 22N to 499 ± 30N
HMB-FA vs. 396 ± 29N to 510 ± 43N PLA (both P < 0.05)). In addition, maximal voluntary contraction
(MVC) also increased (179 ± 12 Nm to 203 ± 12 Nm HMB-FA vs. 185 ± 10 Nm to 217 ± 11 Nm PLA (both
P < 0.05); with no group differences. VL muscle thickness increased signiﬁcantly in the exercised leg in
both groups, with no group differences. TLM (by DXA) rose to signiﬁcance only in the HMB-FA group
(by 5.8%e5734 ± 245 g p ¼ 0.015 vs. 3.0% to 5644 ± 323 g P ¼ 0.06 in PLA). MPS remained unchanged in
the untrained legs (UT) 0e2 weeks being 1.06 ± 0.08%.d1 (HMB-FA) and 1.14 ± 0.09%.d1 (PLA), the
trained legs (T) exhibited increased MPS in the HMB-FA group only at 0e2-weeks (1.39 ± 0.10%.d1,
P < 0.05) compared with UT: but was not different at 4e6-weeks: 1.26 ± 0.05%.d1. However, there were
no signiﬁcant differences in MPS between the HMB-FA and PLA groups at any given time point and no
signiﬁcant treatment interaction observed. We also observed signiﬁcant inductions of c-Myc geneal voluntary contraction; RET, Resistance exercise training; 1-RM, One repetition maximum; TC/EA, High temperature
hy; IRMS, Isotope ratio mass spectrometer; MPS, Muscle protein synthesis; USG, Ultrasonography; DXA, Dual-energy
eMethoxycarbonyl methyl ester; APE, Atom percent excess; RPE- Rating of perceived exertion, PLA- Placebo; HMB,
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RET with adjuvant HMB-FA supplements in free-living healthy older men did not enhance muscle
strength or mass greater than that of RET alone (PLA). That said, only HMB-FA increased TLM, supported
by early increases in chronic MPS. As such, chronic HMB-FA supplementation may result in long term
beneﬁts in older males, however longer and larger studies may be needed to fully determine the
potential effects of HMB-FA supplementation; translating to any functional beneﬁt.
© 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Table 1
Shows baseline demographics for both groups, there were no signiﬁcant differences
between the groups.
Placebo Treatment
Age (y) 68.5 ± 1.0 67.8 ± 1.1
Height (m) 1.74 ± 0.02 1.76 ± 0.02
Weight (kg) 83 ± 2.9 86 ± 4.1
BMI (kg.m2) 27 ± 0.9 28 ± 1.2
ASM (kg) 24.8 ± 1.1 25.3 ± 1.3
ASMI (ASM kg.m2) 7.8 ± 0.3 8.5 ± 0.4
Thigh Lean Mass (kg) 5.5 ± 0.3 5.6 ± 0.31. Introduction
Age-related loss of skeletal muscle mass and function is a well-
established hallmark of sarcopenia [1]. In spite of the fact that
clinical diagnostics for sarcopenia are not yet available, there have
been a number of iterations of deﬁning criteria, including those
based on lowmuscle mass for age [2], or more recently, composites
of low muscle mass and function [3]. However, despite some
progress in deﬁning sarcopenia, there remains no widely accepted
pharmacological therapy to treat it. This has led to a host of
research aimed at testing adjuvant nutritional and exercise in-
terventions that may be able to facilitate skeletal muscle mainte-
nance in older age.
Resistance exercise training (RET) remains the most potent
anabolic stimulus in relation to skeletal muscle tissue, through the
induction of cellular hypertrophy [4].Muscle growth associatedwith
RET is also accompanied by functional improvements [5,6] such as
increases in isokinetic/isometric strength and in power, making this
an attractive intervention for maintenance of muscle function in
older age. That being said, gains in muscle mass are blunted in
older agewhen compared to those inyounger people [6,7] andmeta-
analyses suggest that gains in lean mass with long-term RET equate
to just ~1 kg in older people [8]. Thus, novel strategies to bolster
anabolic responses to RET in older age are needed.
In order for skeletal muscle hypertrophy to occur, sufﬁcient
exogenous amino acids (derived from dietary protein sources) are
required. This is perhaps why protein supplements have been
shown to incrementally enhance RET-induced gains inmuscle mass
in both younger and older adults alike [9]; though whether this
“effect” is a facet only impacting those with lower habitual intakes
remains unknown. Beyond protein supplementation, the post-
transamination product of leucine/alpha-ketoisocaproic acid,
Beta-Hydroxy Beta-Methylbutyrate (HMB) has received consider-
able attention as an ergogenic nutraceutical (i.e. a performance
enhancing nutritional supplement) either alone or in tandem with
RET [10]. HMB has many purported mechanisms of action (sum-
marised in the following review [11]) but in terms of promoting
muscle hypertrophy, has been shown to stimulate muscle protein
synthesis (MPS) and suppress muscle protein breakdown (MPB)
acutely in younger males [12]. There have been numerous studies
investigating the efﬁcacy of HMB supplements alongside RET.
For example, chronic HMB supplementation has been shown to
increase muscle mass and strength in younger individuals under-
going RET [13] and also in older women undertaking a twiceweekly
exercise programme [14]. Similarly, long term (~1y) supplementa-
tion with a HMB/arginine/lysine mixture improved muscle mass
and strength in non-vitamin D deﬁcient older adults [15]. This is
further supported by a two-phase study whereby calcium HMB
supplements alone improved muscle mass gains compared to a
placebo, although there was no additive impact with RET, [16].
Finally, despite varying reports of efﬁcacy [11], a meta-analysis
concluded that HMB supplements contribute to the preservation
of muscle mass in old age [17].t al., A double-blind placebo c
uscle mass and function,In the present study, we aimed to determine the impact of HMB
supplementation in older males undertaking unilateral RET, and to
deﬁne the underlying mechanisms of any effects of HMB using
newly developed techniques that permit the long-termmeasures of
MPS via deuterium oxide (D2O) [5,6,18]. Furthermore, we adopted
the use of the free acid (HMB-FA) rather than the calcium form
(Ca-HMB) of HMB, since greater bio-availability of HMB-FA has
been shown in humans [19,20]. We hypothesised HMB-FA sup-
plementation would enhance muscle mass gains with/without RET
by enhancing MPS.
2. Materials and methods
2.1. Subject characteristics and ethics
Sixteen healthy older males were recruited and randomly
assigned (8 per group) to either HMB-FA (Age 67.8 ± 1.1 y, BMI
28 ± 1 kg m2) or the placebo (Age 68.5 ± 1.6 y, BMI 27 ± 1 kg m2)
group; see Table 1 for subject characteristics. Sample size was
powered based on the primary end point of chronic MPS. A sample
size of 8 in each group was determined to have a >80% power to
detect a mean difference inMPS of 25% assuming that the pooled SD
of chronic MPS measures is 0.23 (based on previous data from our
lab [5,6,18], and a Cohen's d estimation of effect size of 1.55 using a
two-group unpaired t-test with a 0.05 two-sided signiﬁcance.
All power calculations were performed using the pwr R package
(https://cran.rproject.org/web/packages/pwr/index.html). All vol-
unteers were screened by medical questionnaire, physical exami-
nation, and resting electrocardiogram, with exclusions for
metabolic, respiratory, and cardiovascular disorders or any other
symptoms of ill health. Subjects had normal blood chemistry, were
normotensive andwere not prescribed anymedications; all subjects
performed activities of daily living and recreation but did not un-
dertake in any RET other than that described in the study and had
not recently participated in any RET. All subjects provided their
written, informed consent to participate after all procedures and
risks (in relation to muscle biopsies, blood sampling, etc.) were
explained. This study was approved by The University of Notting-
ham Ethics Committee and complied with the Declaration of Hel-
sinki and registered at https://clinicaltrials.gov/(NCT02505438).
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2.2. Conduct of the study
This study involved a bilateral protocol whereby one leg was
used as an untrained (UT) internal control with the other leg acting
as the trained (T) leg, with the dominant leg assigned as T. Following
inclusion to the study, subjects were studied over a 6-week period.
On the ﬁrst day of study, subjects arrived at the laboratory at 0830 h
following an overnight fast. Following assessment of Vastus Lateralis
(VL) skeletal muscle architecture by ultrasound (Mylab 70; Esaote
Biomedical) and body composition by dual-energy X-ray absorpti-
ometry (DXA; Lunar Prodigy II, GE Medical Systems, Little Chalfont,
Buckinghamshire, UK), subjects completed the 1st session of RET
consisting of unilateral knee-extension exercise (i.e. 6  8 reps at
75% 1-RM). Bilateral biopsies were taken from VLmuscle 75 ± 2min
after unilateral exercise under sterile conditions, using the con-
chotome biopsy technique [21] with 1% lidocaine (B. Braun Mel-
sungen) as local anaesthetic. Muscle was rapidly dissected free of fat
and connective tissue, washed in ice-cold PBS, blotted to remove
excess water, frozen rapidly in liquid N2, then stored at 80 C until
further analysis. Immediately post-RET, subjects provided a saliva
sample (collected in sterile plastic tubes) then consumed a 200 ml
bolus of D2O (70 atom%; SigmaeAldrich, Poole, UK); with the aim to
label the body water pool to ~0.2% atom percent excess (APE); this
dosing protocol was repeated at week 4 thereby providing two
distinct periods of measurement of MPS. In addition, venous blood
samples were collected into lithium heparin coated tubes, imme-
diately cold centrifuged at 1750 g, with plasma fractions aliquoted
and frozen at 80 C until analysis. Thereafter, subjects returned to
the lab 3 $ wk1 to undertake supervised unilateral RET with 1-RM
assessments of the T leg every ~10 d to ensure progressive intensity.
Further bilateral muscle biopsies (~75 min after RET in order to
investigate the temporal nature of acute anabolic signalling re-
sponses to progressive RET), ultrasound measures of muscle archi-
tecture and venous blood samples were taken at 0, 2, 4 and 6-weeks
and muscle thickness and lean thigh mass by DXA at 0, 3 and
6-weeks. For the temporal monitoring of body water enrichment,
each participant provided a saliva sample on RET-visits at least
30 min after their last meal or drink, with extra samples taken ~3 h
after bolus top-ups to ensure bodywater enrichment was accurately
determined over time. These were collected in sterile plastic tubes
and immediately cold centrifuged at 16,000 g to pellet any debris;
they were then aliquoted into 2-ml glass vials and frozen at 20 CFig. 1. Study
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protocol is depicted in Fig. 1.
2.3. Exercise training protocol
The 1 repetition maximum (1-RM) was determined for the
dominant leg prior to the study beginning. Supervised unilateral
RET (leg extension of the dominant leg, 6 sets of 8 reps at 75% 1-RM,
three times weekly) was performed over 6 weeks. RET was
progressive and the 1-RM, and MVC was assessed every 10 days.
This intensity of exercise has previously been shown to maximize
MPS responses acutely in older males [22].
2.4. Treatment supplementation
All subjects were randomly assigned to either placebo or HMB-
FA (3.0 g/d; Metabolic Technologies, Ames, IA); volunteers were
asked to consume the supplement daily at breakfast. Each HMB-FA
sachet consisted of 1 g of b-hydroxy-b-methylbutyric free acid
(BetaTOR®), Litesse polydextrose, reverse osmosis water, debittering
agent, orange ﬂavour, stevia extract, potassium carbonate and
potassium sorbate; each sachet of placebo consisted of a similar
amount of Litesse polydextrose, reverse osmosis water, corn syrup,
debittering agent, orange ﬂavouring, stevia extract, citric acid, po-
tassium sorbate, and xanthin gum powder. Supplements were ob-
tained in identical plain packaging, coded by the manufacturer, all
investigators remained blinded until study and analyses were
completed. Volunteers were ﬁrst assigned to a lettered group, by a
clinical measurement technician (AG, see acknowledgments), based
on random allocation using a sealed envelope; then received the
supplements weekly (3 sachets per day), and a log of returned
sachets was kept to informupon compliance, whichwas excellent in
both groups (100% PLA vs 99% HMB). Blood samples were collected
weekly immediately prior to the RET for themeasurement of plasma
HMB concentrations.
2.5. Muscle functional tests
Measures of maximal voluntary contraction (MVC) and one
repetition maximum (1-RM) were assessed. MVC was measured
with isometric contractions conducted in a sitting position using an
isokinetic dynamometer (Isocom; Isokinetic Technologies, Euro-
kinetics) over a range of four knee joint angles (60, 70, 80 & 90),
with full extension corresponding to 0. Subjects were seated in the
dynamometer chair and secured into position using a chest strap.protocol.
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and 90 s between knee joint angles. Unilateral leg extension 1-RM
was assessed on the dominant leg (Technogym, Gambettola, Italy).
Following explanation of the procedure, subjects performed a light
warm up to avoid injury and ensure familiarity whilst avoiding
fatigue; 1-RM was then achieved (20 on Borg's RPE scale) in as few
repetitions as possible with a maximum of 5 repetitions. The ﬁrst
repetition was estimated at 50% 1-RM and then increased until
subjects could not complete controlled contraction throughout the
range of motion, with 3 min rest in-between attempts.
2.6. Muscle architecture, DXA derived mass
Muscle architecture was measure as described [18]. Brieﬂy, the
architectural parameter of muscle thickness (MT), was quantiﬁed
from ultrasound scans using Image J 1.42q (National Institutes of
Health, Bethesda, MD). The MT was measured as the distance
between the superﬁcial and deep aponeuroses (Franchi et al., 2014).
DXA derived quadriceps muscle mass was determined from the
lowest point of the ischium to the knee space.
2.7. Body water and protein bound alanine muscle fraction
enrichment
Body water and muscle protein enrichment was measured as
previously described [18]. Saliva was heated in a vial at 100 C, then
cooled rapidly on ice and the condensate transferred to a clean vial
ready for analysis. Deuterium enrichment was measured on a high-
temperature conversion elemental analyser connected to an
isotope ratio mass spectrometer (TC/EA-IRMS Thermo Finnigan,
Hemel Hempstead, UK). Myoﬁbrillar proteins were extracted as
previously described; brieﬂy, the myoﬁbrillar fraction was isolated
by centrifugation from the sarcoplasmic protein solubilized in 0.3M
NaOH and separated from the insoluble collagen by centrifugation.
The protein was then precipitated, acid hydrolysed, and the free
amino acids were puriﬁed and derivatised as their n-methox-
ycarbonyl methyl esters (MCME) (Wilkinson 2014). Incorporation
of deuterium into protein bound alanine was determined by
gas chromatography-pyrolysis-isotope ratio mass spectrometry
(GC-pyrolysis-IRMS, Delta V Advantage; Thermo Finnigan, Hemel
Hempstead, UK) alongside a standard curve of known DL-Alanine-
2,3,3,3-d4 enrichment to validate measurement accuracy.
2.8. Calculation of FSR
Myoﬁbrillar MPS was calculated from the incorporation of
deuterium-labelled alanine into protein, using the enrichment of
body water (corrected for the mean number of deuterium moieties
incorporated per alanine, 3.7, and the dilution from the total number
of hydrogens in the derivative, 11) as the surrogate precursor
labelling between subsequent biopsies. The equation used was:
FSR ¼ Ln
0
@1
hðAPEalaÞ
ðAPEpÞ
i
t
1
A
where APEAla ¼ deuterium enrichment of protein-bound alanine,
APEP ¼ Mean precursor enrichment over the time period, and t is
the time between biopsies.
2.9. RNA extraction
Muscle biopsies were taken from both rest and exercise legs of
the subjects at 0, 2, 4 and 6-week time points. Muscle tissue
(5e10 mg) was chipped, homogenized in TRIzol Reagent and lysedPlease cite this article in press as: Din USU, et al., A double-blind placebo c
on free-living muscle protein synthesis, muscle mass and function,
j.clnu.2018.09.025(TissueLyserII, QIAGEN). The RNA was extracted in the upper
aqueous phase, then precipitated with isopropanol, washed, taken
up in RNase free water, then the purity and quantity were assessed
(NanoDrop Lite, Thermo Scientiﬁc). A ratio of 1.7e2.0 was accepted
as ‘pure’ for RNA. An aliquot of RNA was then reverse transcribed
(High Capacity cDNA Reverse Transcription Kit; Life Technologies)
according to the manufacturer's instructions and stored at 20 C
until qRT-PCR was performed.
2.10. Measurement of gene expression by qRT PCR
2.10.1. Primer design
Real-time RT-PCR exon speciﬁc primers were designed for
myostatin, MyoD, myogenin, humanmuscle atrophy F-box (MAFbx/
Atrogin-1), human calpain, Ubiquitin, cMyc, Muscle RING-ﬁnger
protein-1 (MURF1), Myogenic factor 5 (MYF5), REDD1 (regulated
in development and DNA damage responses 1), eIF3f (eukaryotic
translational initiation factor 3, subunit F) and Peptidylprolyl
isomerase A (PPIA3) gene using Primer express software. Finally, all
sequences were submitted to the Primer blast software, available on
the National Centre for Biotechnology Information website (www.
ncbi.nlm.nih.gov), in order to evaluate gene speciﬁcity. All mRNA-
speciﬁc primers were validated before use.
All measures were carried out in triplicate, and the values of
ampliﬁcation were normalized to the “housekeeping gene” Pepti-
dylprolyl isomerase A (PPIA3), in each biopsy and compared to the
control leg on Day 0, since its expression remains unaltered with
exercise. Sybr-Green real-time RT-PCR analyses were carried out on
the iQ5 real-time PCR detection system (Bio-Rad). A melt curve was
run at the end of each qRT-PCR assay to validate product speciﬁcity.
For each qRT-PCR experiment, a standard curve was generated for
each target gene. The relative gene expressionwere calculated using
the 2DCT method [23]. This method generates a value in arbitrary
units (AU) of the gene of interest (GOI) expression normalized to the
housekeeping gene (HKG) expression (DCT ¼ CTGOI - CTHKG).
2.11. Statistical analyses
Descriptive statistics were produced for all data sets to
check for normal distribution (accepted if P > 0.05) using a
KolmogoroveSmirnov test. Data from all subjects (n¼ 8 per group)
are presented as means ± SEM. Myoﬁbrillar protein synthesis rates
and all other data sets were analysed by repeated measures two-
way ANOVA with a Bonferroni correction using GraphPad Prism
(La Jolla, CA) Software Version 5. The a level of signiﬁcance was set
at P < 0.05.
3. Results
3.1. 1-RM and MVC in rest and exercise legs (Fig. 2)
Over the 6-week period, RET increased 1-RM linearly in the
trained leg in both groups, (baseline 396 ± 29N to 510 ± 44N, þ29%
(PLA) and 398 ± 22N to 499 ± 31N, þ25% (HMB-FA), both p < 0.01
compared to baseline, with no difference between the groups).
Similarly, MVC increased progressively in the trained leg of both
groups (baseline 185 ± 10 Nm vs. 217 ± 11 Nm, þ18% (PLA) and
179 ± 12 Nm to 203 ± 12 Nm, þ16% (HMB-FA) at 6 weeks, both
p < 0.05 vs baseline, with no differences between groups). Both 1-
RM and MVC were unchanged in the control legs of either group.
3.2. Muscle mass and architecture in rest and exercise legs (Fig. 3)
Thigh lean mass assessed by DXAwas not signiﬁcantly different
between the groups at the start of the study (i.e. baselineontrolled trial into the impacts of HMB supplementation and exercise
in older adults, Clinical Nutrition (2018), https://doi.org/10.1016/
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U.S.U. Din et al. / Clinical Nutrition xxx (2018) 1e8 55423 ± 321 g PLA vs 5476 ± 221 g HMB-FA), with only the HMB-FA
group signiﬁcantly increasing lean muscle mass in the trained leg
(Fig 3, 5734 ± 245 g at 6 weeks HMB-FA, P < 0.05 vs 5644 ± 323 g
PLA, P¼ 0.06). Thigh fat freemasswas unchanged in the control legs
of both groups (5338 ± 300 g to 5311 ± 274 g PLA, and 5399 ± 262 g
to 5470 ± 237 g HMB-FA). There were no differences between the
groups at any time. Measures of VL architecture (Fig. 3) revealed
signiﬁcant increases in MT over 6 weeks in exercise legs of both
groups (20.7 ± 0.6 mm to 22.4 ± 0.7 mm PLA, and 21.7 ± 0.9 mm to
23.3 ± 1.1 mm HMB-FA, both P < 0.01. Muscle thickness was
unchanged over the 6week period in the control leg in both placebo
and HMB-FA groups. Pennation angle increased signiﬁcantly in the
exercised leg in both groups by 6 weeks (14.1 ± 1.8 to 15.2 ± 1.5
PLA, and 13.7 ± 1.5 to 14.7 ± 1.8 HMB-FA P < 0.05) and was
unchanged in the control leg over the same period. Fibre length (Lf)
was increased signiﬁcantly in the exercised leg in both groups at 6
weeks (79.7 ± 2.8 cm to 83.1 ± 3.3 cm PLA, and 81.0 ± 6.1 cm to
84.0 ± 6.4 cm HMB-FA, both P < 0.001, with no difference between
the groups).1 2 3 4 5 6 
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Fig. 4. Plasma HMB concentration in the treatment (HMB-FA) and placebo groups
following oral consumption of treatment or placebo. Statistical signiﬁcance (p < 0.05)
a ¼ different from respective basal, b ¼ different between groups at equivalent
time-point.3.3. Plasma HMB concentrations
Plasma HMB concentration was signiﬁcantly increased
throughout only in subjects in the treatment group (Fig. 4), whereas
plasma HMB remained constant (i.e. at baseline, ~2.4 ± 0.2 mM)
throughout the study in the placebo group.
3.4. D2O-derived muscle protein synthesis (MPS) in rest and
exercised legs of placebo and treatment group (Fig. 5)
Over 0e2 weeks there was no signiﬁcant treatment interaction
between the PLA and HMB-FA groups, however signiﬁcantPlease cite this article in press as: Din USU, et al., A double-blind placebo c
on free-living muscle protein synthesis, muscle mass and function,
j.clnu.2018.09.025increases in MPS were displayed from 0 to 2 weeks in the exercise
leg with HMB-FA supplementation only (1.06 ± 0.08%.d1 Rest
vs 1.39 ± 0.10%.d1 Exercise, P < 0.05, thereafter returning to
1.26 ± 0.05%.d1 at 4e6 weeks). MPS rose slightly but not signiﬁ-
cantly in the exercised leg of the placebo group (1.14 ± 0.09%.d1
Rest vs 1.36 ± 0.10%.d1 Exercise, thereafter returning to
1.23 ± 0.05%.d1 at 4e6 weeks). MPS was not different between
legs nor treatments over 4e6 weeks. In addition, we did not ﬁnd
any signiﬁcant differences in MPS between placebo or treatment at
any time-point.ontrolled trial into the impacts of HMB supplementation and exercise
in older adults, Clinical Nutrition (2018), https://doi.org/10.1016/
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Fig. 5. Depicts time course of changes in muscle protein synthesis (MPS) over 0e2 and
4e6 weeks in both rest and exercised legs of placebo and treatment (HMB-FA) groups.
*P < 0.05 statistically signiﬁcant in trained leg of treatment group as compared to
rest leg.
U.S.U. Din et al. / Clinical Nutrition xxx (2018) 1e863.5. Expression of genes involved in muscle hypertrophy/atrophy
and myogenesis
Of all the genes measured (see Table 2), only cMyc mRNA
expression changed signiﬁcantly (P < 0.05) in response to an acute
bout of RET. In both the placebo and treatment groups, cMyc mRNA
expression levels were elevated in the trained leg at 0, 2 and 4
weeks compared to the untrained leg at each timepoint. However,
this responsewas ameliorated in both groups at week 6. Therewere
no changes in cMyc expression in the rest leg in either group at any
time-point and no signiﬁcant differences between the placebo and
treatment groups at any time point.
4. Discussion
In the present study, we sought to determine the effects of HMB-
FA supplementation adjunct to RET on muscle function and mass in
older aged men. Further using D2O, we aimed to make the ﬁrst
longer-term measures of the effect of HMB-FA on MPS. Our results
show that gains in muscle function (i.e. 1RM, MVC) and muscle
mass induced by 6 weeks of RET were largely similar between the
groups. Nonetheless, HMB-FA supplementation exhibited a
marginally more favourable response in relation to gains in thigh
fat freemass over placebo, supported by an enhanced early increase
in MPS over the ﬁrst two weeks of RET.
The anabolic efﬁcacy of HMB has already been trialed in many
scenarios, including to enhance muscle mass and function in
relation to athleticism, ageing, and cachectic diseases [11]. In thePlease cite this article in press as: Din USU, et al., A double-blind placebo c
on free-living muscle protein synthesis, muscle mass and function,
j.clnu.2018.09.025present study, we found that HMB-FA supplementation provided
some incremental effect in relation to muscle hypertrophy as
evidenced by increases in thigh fat free mass by DXA. However, we
were unable to identify any differences when quantifying muscle
thickness by ultrasound. Both DXA and ultrasound measures of
muscle mass have inherent limitations; for instance, DXA tends
to overestimate absolute skeletal muscle contractile mass [24].
Contrarily, ultrasound measures of muscle thickness tend to be
made at a single point along the VLmuscle, so it does not account for
muscle cross sectional area, nor necessarily reﬂect the entire VL nor
indeed the thigh muscles as a whole. From our data, we can only
conclude that the positive inﬂuence of HMB-FA on thigh fat free
mass by DXA reﬂects a small but generalized improvement in thigh
muscle mass, not reﬂected by measuring VLmuscle thickness alone.
These data demonstrating improvements inmuscle mass gains with
HMB-FA vs. placebo are also in line with other studies [16], although
unlike this previous study we did not see any changes in muscle
mass of the non-exercising leg. We speculate that the greater
duration of that study and greater subject numbers might explain
this difference. Likewise, we have observed improvements in func-
tional measures of muscle strength such as 1-RM andMVC after just
3 weeks of RET in both groups, which is in agreement with studies
previously performed showing an increase in muscle strength
coupledwithmuscle hypertrophy (Rabita et al., 2000; Seynnes et al.,
2007), suggesting earlier adaptive responses to training than pre-
viously reported (Fatouros et al., 2006; Granacher et al., 2009). We
observed an increase in 1-RM after 6 weeks of training in both
groups, with similar improvements between the treatment and
placebo groups by the end of study period; in contrast to some
studies reporting a signiﬁcant gain in strength and functionality
with HMB supplementation compared to the placebo [29,30].
However, it has to be taken into account that these studies were
conducted over longer periods (8 and 12 weeks, respectively).
Further, one study also included supplementation of lysine and
arginine in addition to HMB [30]. It is possible that the rapid neural
adaptations known to predominate during the early stages of a
resistance training program could have masked any additional
beneﬁcial effect of HMB-FA onmuscle strength during this relatively
short training duration. In terms strength improvements assessed
by MVC, there was an accelerated response in the HMB-FA group
initially, as we observed signiﬁcant improvements by 3 weeks of
study period in the HMB-FA group only, although both the groups
increased signiﬁcantly in MVC strength by the end of the study.
A similar randomised double blind placebo controlled trial
carried out in two phases previously reported that body composi-
tion, muscle function and strength in older individuals (>65, men
and women) were enhanced by calcium HMB (Ca-HMB) supple-
mentation without RET [16]. They conducted the study over a
period of 24 weeks in two phases where placebo or 3 g/d Ca-HMB
was given to older men and women either alone (Phase I) or in
combination with RET (Phase II). The results of phase II of this
study, which was similar to our study design where effects of Ca-
HMB were seen in combination with RET, stated that total, arm
and leg lean mass, muscle strength and function increased signif-
icantly in both RET groups however there no group differences, this
is consistent with our ﬁndings; our study is novel in that we have
also measured myoﬁbrillar MPS in addition to the expression of a
number of genes involved in muscle hypertrophy/atrophy and
myogenic regulatory factors in response to each acute RET bout
coupled with PLA vs HMB-FA supplementation.
The mechanisms by which HMB might impose efﬁcacy include
its known acute actions upon stimulating MPS and suppressing
MPB [12]. To seek mechanistic explanations for any effects of RET/
HMB interventions, we quantiﬁed MPS using D2O methodologies.
Despite there being no treatment interaction between PLA andontrolled trial into the impacts of HMB supplementation and exercise
in older adults, Clinical Nutrition (2018), https://doi.org/10.1016/
Table 2
Muscle mRNA expression.
Groups BASAL 2 week 4 week 6 week
Rest Acute RET Rest Acute RET Rest Acute RET Rest Acute RET
cMyc
50-GGTAGTGGAAAACCAGCAGCC-30 PLA 1.0 ± 0.7 3.0 ± 2.0* 1.0 ± 0.6 4.9 ± 0.7* 0.6 ± 0.4 3.0 ± 3.3* 1.2 ± 1.3 2.2 ± 1.0
50-TCTCCTCCTCGTCGCAGTA-30 HMB 0.9 ± 0.6 3.0 ± 1.9* 1.9 ± 3.8 3.0 ± 1.9* 0.6 ± 0.3 2.6 ± 1.7* 1.5 ± 2.2 1.7 ± 2.0
Myostatin
50-GCTGCGCCTGGAAACAGCTC-30 PLA 1.0 ± 0.3 1.1 ± 0.6 1.7 ± 1.3 1.0 ± 0.4 1.1 ± 0.5 0.8 ± 0.3 1.0 ± 0.6 1.4 ± 0.8
50-ATCAGTTCCCGGAGTGGAGGC-30 HMB 1.3 ± 0.7 1.1 ± 0.5 1.6 ± 0.8 0.8 ± 0.3 1.1 ± 0.6 1.0 ± 0.7 0.9 ± 0.5 1.1 ± 0.4
Myogenin
50-ACCCTACAGATGCCCACAAC-30 PLA 1.0 ± 0.4 0.7 ± 0.4 1.1 ± 0.9 0.7 ± 0.2 0.4 ± 0.3 0.9 ± 0.8 1.0 ± 0.6 0.9 ± 0.6
50-GGAAGGCCACAGACACATCT-30 HMB 0.5 ± 0.2 1.0 ± 0.5 0.5 ± 0.3 0.7 ± 0.4 1.3 ± 0.9 0.5 ± 0.2 1.2 ± 1.5 0.6 ± 0.3
MyoD
50-CTCCGACGGCATGATGGACTA-30 PLA 1.0 ± 0.6 0.8 ± 0.4 1.3 ± 0.5 0.8 ± 0.6 0.5 ± 0.4 0.5 ± 0.3 0.6 ± 0.3 0.9 ± 0.5
50-TGGGCGCCTCGTTGTAGTA-30 HMB 2.5 ± 1.5 1.9 ± 1.1 3.3 ± 1.3 2.1 ± 1.6 1.1 ± 1.0 1.2 ± 0.7 1.6 ± 0.7 1.3 ± 1.3
Myf5
50-ATGCCCGAATGTAACAGTCCT-30 PLA 1.0 ± 0.5 1.0 ± 0.5 0.7 ± 0.3 0.7 ± 0.4 0.3 ± 0.2 0.6 ± 0.4 0.7 ± 0.3 1.0 ± 0.6
50-GGTTGCTCTGAGGAGGTGAT-30 HMB 0.9 ± 0.8 0.5 ± 0.5 0.8 ± 0.9 0.7 ± 0.6 0.5 ± 0.3 0.6 ± 0.3 0.6 ± 0.4 0.7 ± 0.4
eIF3f
50-GTTGGGAACTGTCGACAAAC-30 PLA 1.0 ± 0.5 0.9 ± 0.3 0.7 ± 0.2 1.0 ± 0.7 0.5 ± 0.3 0.6 ± 0.2 0.6 ± 0.2 0.9 ± 0.5
50-ATTCCATGTCAACAGCCACT-30 HMB 0.8 ± 0.4 0.7 ± 0.3 0.7 ± 0.2 0.7 ± 0.5 0.5 ± 0.2 0.6 ± 0.3 0.6 ± 0.1 0.5 ± 0.1
REDD1
50-AAGACACGGCTTACCTGGA-30 PLA 1.0 ± 0.6 1.0 ± 0.6 0.8 ± 0.4 0.5 ± 0.2 0.4 ± 0.2 0.6 ± 0.5 0.8 ± 0.4 1.0 ± 0.9
50-CAGTAGTTCTTTGCCCACCT-30 HMB 0.9 ± 0.6 0.9 ± 0.6 0.6 ± 0.3 0.7 ± 0.4 0.5 ± 0.3 1.1 ± 0.8 0.8 ± 0.4 0.4 ± 0.1
MURF1
50-AGTGACCAAGGAGAACAGTCA-30 PLA 1.0 ± 1.2 2.3 ± 1.6 0.6 ± 0.3 1.5 ± 1.6 0.4 ± 0.3 0.6 ± 0.4 0.5 ± 0.4 0.6 ± 0.4
50-CACCAGCTTTGTGGACTTGT-30 HMB 0.4 ± 0.2 0.8 ± 0.4 0.3 ± 0.2 0.7 ± 0.6 0.2 ± 0.1 0.6 ± 0.4 0.4 ± 0.2 0.4 ± 0.2
MAFbx
50-CCTTCACTGACCTGCCTTT-30 PLA 1.0 ± 0.5 1.8 ± 1 0.8 ± 0.5 0.7 ± 0.7 0.7 ± 0.9 0.6 ± 0.3 0.4 ± 0.2 0.7 ± 0.4
50-CCTTCACTGACCTGCCTTT-30 HMB 0.6 ± 0.4 0.5 ± 0.3 0.4 ± 0.2 0.6 ± 0.5 0.3 ± 0.2 0.5 ± 0.4 0.4 ± 0.2 0.3 ± 0.1
Ubiquitin
50-GATCTGCCGCAAGTGCTA-30 PLA 1.0 ± 2.0 1.1 ± 1.6 1.1 ± 2.4 1.1 ± 2.4 0.5 ± 1.2 0.6 ± 0.6 0.4 ± 0.6 0.5 ± 0.8
50-CAGTCAATGAAAGGGACACT-30 HMB 0.6 ± 1.0 0.4 ± 0.3 0.6 ± 1.2 0.6 ± 1.1 0.5 ± 0.7 0.5 ± 0.7 0.4 ± 0.9 0.3 ± 0.4
Calpain
50-GCCAAGCAGGTGAAC-30 PLA 1.0 ± 1.0 0.7 ± 0.4 0.7 ± 0.3 1.2 ± 1.1 0.4 ± 0.3 0.5 ± 0.3 0.5 ± 0.3 0.7 ± 0.5
50-TGAAGTCTCGGAATGACATC-30 HMB 0.45 ± 0.3 0.3 ± 0.1 0.4 ± 0.3 0.6 ± 0.4 0.5 ± 0.3 0.3 ± 0.1 0.4 ± 0.2 0.4 ± 0.2
*Signiﬁcantly different from rest leg at each timepoint and within in each condition P < 0.05.
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increases in the HMB-FA group only. We have previously shown
that muscle adaptation is most active during the ﬁrst 3 weeks of an
RET program [4]; with MPS robustly increased during this active
period of muscle growth, becoming attenuated thereafter despite
progressive training [31]. Our inability to distinguish signiﬁcant
differences between HMB-FA vs. placebo groups at any given
timepoint likely reﬂects the small incremental effects on muscle
mass gains apparently induced by HMB-FA supplementation, an
effect that may have become prevalent with a larger cohort as
our study was primarily powered to investigate MPS increases.
Nonetheless, we cannot conclude that a suppression of MPB might
also be a more dominant mechanism of HMB's anabolic actions
in relation to RET in humans. Long term measures of MPB are
technically challenging, but “reverse labelling” D2O approaches
may be feasible options to determine the impact of HMB (or other
interventions) on both MPS/MPB in future.
With a view to seek potential gene level regulation of RET/HMB
interventions, we also quantiﬁed the expression of a number of
genes that have been associated with muscle anabolism (i.e. those
that regulate myogenesis/ribosomal biogenesis) in response to
acute bouts of RET. In doing so we found that acute RET had a
minimal impact upon most of the genes we measured; this may be
related to a blunted gene expression response to exercise in older
age [32], although without a direct comparison to a younger group
herein, this remains speculation. In contrast c-mycwas upregulated
consistently after bouts of RET and represented a robust
“biomarker” of acute responses to RET; c-myc is an oncogene
regulating cellular growth and has been long known to be regulated
by muscle loading [33] and in this report was even shown to be
blunted in an avian model of muscle stretch induced hypertrophy.Please cite this article in press as: Din USU, et al., A double-blind placebo c
on free-living muscle protein synthesis, muscle mass and function,
j.clnu.2018.09.025Nonetheless, c-Myc was clearly and consistently upregulated in
our group of older men, although this was unaffected by HMB-FA
supplementation. As such, from the targeted gene data we have
here, HMB-FA had no impact upon the expression of many key
growth genes either in non-exercising or exercising human skeletal
muscle. It is possible that, due to the timing of the muscle biopsy,
we may have missed the acute upregulation of some of the genes
we measured [34,35], however, we saw no effect of chronic
HMB-FA supplementation in the non-exercise limb over 6 weeks. It
could be argued thus, that the major effects of HMB-FA are through
post-translational effects on signalling pathways regulating MPS
and MPB; many studies support this notion [36].
In conclusion, we have shown that HMB-FA supplements appear
to induce a marginal improvement in muscle mass gains (via DXA),
in line with previous studies in this area [16]. Nonetheless, this did
not translate into functional improvements as assessed by isometric
and isokinetic (1-RM) strength tests. MPS was signiﬁcantly elevated
during the ﬁrst twoweeks only in theHMB-FA supplemented group,
returning to baseline levels during the last two weeks, similar to the
response we observed previously in young healthy male volunteers
undertaking an identical training regime [4]. Nonetheless, the pre-
sent study adds to the current weight of literature that tends to
favour efﬁcacy of HMB and HMB containing supplements in ageing,
in relation to skeletal muscle outcomes [37].Funding sources
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